British Pharmacopoeia 2026
The British Pharmacopoeia 2026 — the UK's official collection of standards for medicinal substances and formulated preparations, published by the MHRA through the British Pharmacopoeia Commission and legally effective from 1 January 2026 under the Human Medicines Regulations 2012. It incorporates the European Pharmacopoeia texts alongside BP-specific monographs, notably for formulated preparations, where the BP's coverage exceeds the Ph. Eur.'s.
What this does not cover
stated in the document's own scope- Sets product standards for the UK market; manufacturing practice is governed by UK GMP (aligned with EU GMP), a separate regime the compendium does not address.
- Incorporates the Ph. Eur., but the reverse does not hold — BP-specific formulated-preparation monographs have no Ph. Eur. equivalent and bind only where the BP is the referenced standard.
- Veterinary standards sit in the companion BP (Veterinary), not in the main volumes.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
The British Pharmacopoeia 2026 is the UK's official collection of quality standards for medicinal substances and formulated preparations, legally effective from 1 January 2026. Published annually by the Medicines and Healthcare products Regulatory Agency through the British Pharmacopoeia Commission, the BP incorporates the texts of the European Pharmacopoeia — the UK remains a Ph. Eur. signatory through the Council of Europe convention — and adds BP-specific monographs on top, most distinctively for formulated preparations, where the BP's finished-product monographs go well beyond the Ph. Eur.'s substance-focused coverage. A companion publication, the BP (Veterinary), carries the standards for veterinary medicines.
Scope & applicability
Medicines marketed in the UK: BP standards are the legally enforceable quality benchmark, and the publication also serves markets worldwide that reference the BP. A companion BP (Veterinary) covers veterinary medicines.
Legal basis & how it acquires force
Published by the MHRA under the Medicines Act 1968 framework as continued in the Human Medicines Regulations 2012, which give BP standards legal effect for medicines marketed in the UK: an article described as complying with the BP must meet the current edition's standard, and the BP 2026 became the legally effective edition on 1 January 2026. Incorporated Ph. Eur. texts carry their European provenance; BP-only monographs are UK national standards.
Document structure
| Part | Covers |
|---|---|
| Medicinal and pharmaceutical substances | Monographs for drug substances, including incorporated Ph. Eur. texts |
| Formulated preparations | The BP's distinctive finished-product monographs — general monographs plus product-specific specifications |
| Herbal drugs, homoeopathic preparations, and blood-related products | Specialised monograph families for these classes |
| Appendices and general notices | Analytical methods, reagents, and the interpretive rules for applying the monographs |
| BP (Veterinary) | The companion volume of standards for veterinary medicinal products |
Key requirements
- Articles covered by a BP monograph comply with its specification
- Ph. Eur. texts incorporated in the BP apply as published, with BP-specific monographs adding UK requirements
- Testing per the BP appendices and general notices, or justified equivalents
Implementation tips
- The BP's formulated-preparation monographs are its distinctive layer — a product meeting the Ph. Eur. substance monograph may still face a BP monograph on the finished dosage form for the UK market
Revision notes
Published annually; the BP 2026 became legally effective on 1 January 2026, superseding the BP 2025 and incorporating the current European Pharmacopoeia texts.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The BP is built on the European Pharmacopoeia: the UK's continued membership of the Ph. Eur. convention means every Ph. Eur. text is reproduced in the BP, so compliance with a Ph. Eur. monograph carries into the BP. The BP's added layer — formulated-preparation monographs and UK-specific texts — is national. The compendium serves markets beyond the UK that historically reference the BP, and the substance-monograph ground it shares with USP and JP is partially harmonised through the Pharmacopoeial Discussion Group's work on the Ph. Eur. side.
BP 2026: frequently asked questions
Quick answers to common questions about BP 2026.
When did the BP 2026 become effective?
On 1 January 2026, under the Human Medicines Regulations 2012 — the BP is published annually, and each edition supersedes its predecessor as the legally effective standard for the UK.
What is the relationship between the BP and the European Pharmacopoeia?
The UK remains a signatory of the Ph. Eur. convention through the Council of Europe, so the BP incorporates all Ph. Eur. texts, adding BP-specific monographs on top — most notably for formulated preparations. Meeting a Ph. Eur. monograph therefore satisfies the corresponding BP text, but not necessarily the BP's additional finished-product monographs.
Who publishes the British Pharmacopoeia?
The MHRA, through the British Pharmacopoeia Commission, which sets the standards with its expert advisory groups. Publication is annual, with the new edition effective each 1 January.
Why do the BP's formulated-preparation monographs matter?
Because the Ph. Eur. is substance-focused: for many finished dosage forms, the BP monograph is the only compendial specification in the European sphere, so UK-market products face a compendial finished-product standard that continental products may not.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.